A Randomized, Double-blinded, Active Controlled Crossover Clinical Trial to Investigate PK, PD and Safety of GBPD002
Phase 1
Completed
- Conditions
- Natural Blood and Blood Product Toxicity
- Interventions
- Biological: Erythropoietin alpha
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Globe Biotech Limited
- Target Recruit Count
- 42
- Registration Number
- NCT05585658
- Locations
- 🇧🇩
Farabi General Hospital, Dhaka, Bangladesh
🇧🇩Globe Biotech Limited, Dhaka, Bangladesh
© Copyright 2025. All Rights Reserved by MedPath